Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hutchison China Ads (HCM)

Hutchison China Ads (HCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,174,468
  • Shares Outstanding, K 133,381
  • Annual Sales, $ 214,110 K
  • Annual Income, $ -74,800 K
  • 60-Month Beta 0.78
  • Price/Sales 14.30
  • Price/Cash Flow N/A
  • Price/Book 8.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.06 +4.44%
on 11/14/19
24.50 -5.96%
on 11/29/19
+0.10 (+0.44%)
since 11/13/19
3-Month
16.47 +39.89%
on 09/30/19
24.50 -5.96%
on 11/29/19
+1.27 (+5.83%)
since 09/13/19
52-Week
16.47 +39.89%
on 09/30/19
34.48 -33.18%
on 12/14/18
-10.96 (-32.24%)
since 12/13/18

Most Recent Stories

More News
Edison issues ADR update on Hutchison China MediTech (HCM)

LONDON, UK / ACCESSWIRE / November 29, 2019 / Hutchison China MediTech (NASDAQ:HCM) has announced that Elunate (fruquintinib capsules) have been included in China's National Reimbursement Drug List (NRDL)...

HCM : 23.04 (-3.19%)
Chi-Med's Elunate(R) (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Elunate (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced...

HCM : 23.04 (-3.19%)
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug designation to surufatinib for the treatment of...

HCM : 23.04 (-3.19%)
Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will share analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress...

HCM : 23.04 (-3.19%)
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

Deutsche Bank today announced that the presentations from the November 13th and 14th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured...

DB : 7.48 (-1.19%)
HCM : 23.04 (-3.19%)
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that its New Drug Application ("NDA") for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine...

HCM : 23.04 (-3.19%)
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 13th and 14th, 2019

Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on November 13th and 14th, featuring live webcast presentations from international companies with...

DB : 7.48 (-1.19%)
HCM : 23.04 (-3.19%)
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial...

HCM : 23.04 (-3.19%)
Edison issues ADR update on Hutchison China MediTech (HCM)

LONDON, UK / ACCESSWIRE / October 10, 2019 / Hutchison China MediTech (NASDAQ:HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumors (NET)....

CKHUF : 8.9450 (+0.17%)
HCM : 23.04 (-3.19%)
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration agreement to evaluate...

HCM : 23.04 (-3.19%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade HCM with:

Business Summary

Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong.

See More

Key Turning Points

2nd Resistance Point 24.39
1st Resistance Point 23.72
Last Price 23.04
1st Support Level 22.65
2nd Support Level 22.25

See More

52-Week High 34.48
Fibonacci 61.8% 27.60
Fibonacci 50% 25.47
Fibonacci 38.2% 23.35
Last Price 23.04
52-Week Low 16.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar